Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InfectiveEnrolling Location: Not specified

    Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) (BiomX BMX-04-001 Part 1) , protocol number NCT05010577

    This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      11

    • Length of Participation:

      189 days

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Not specified

    Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) (BiomX BMX-04-001 Part 2) , protocol number BX004-A NCT05010577

    This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      9

    • Length of Participation:

      192 days

    Contact us about this clinical Trial >
  • BehavioralRecruiting Location: Hobart, Tasmania

    Impact of Beam Feel Good Website for individuals with cystic fibrosis (CF) , protocol number ACTRN12621000725864

    Cystic Fibrosis (CF) is a chronic, life limiting condition, diagnosed usually at birth and is an autosomal recessive disease. Recent studies have indicated many adults with CF have strong beliefs that exercise may be equal or superior to other traditional forms of airway clearance as the mainstay for treatment. A lack of exercise in a daily regimen for an individual with CF has been associated with increased hospitalisations, poorer health outcomes including decline in lung function and decreased quality of life.

    • Age:

      16 Years to 65 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study to evaluate inhaled AR-501 in healthy adults and adults with cystic fibrosis and Pseudomonas aeruginosa (Aridis AR-501-001 MAD cohorts) , protocol number (Aridis AR-501-001 MAD cohorts) NCT03669614

    This study is testing inhaled AR-501, a drug intended to treat infections in the lung. The study will measure the drug’s safety, how well it works, and how the body processes it. Multiple doses of AR-501 will be tested in both healthy adults and adults with cystic fibrosis who are infected with Pseudomonas aeruginosa to find the best dose.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      45% or greater

    • Number of Visits:

      11

    • Length of Participation:

      6 Weeks

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Australia

    BEAT CF platform: A digital infrastructure and data collection tool to evaluate treatments for pulmonary exacerbations in children and adults with Cystic Fibrosis. , protocol number ACTRN12621000638831

    With every respiratory exacerbation of CF, approximately 25% of patients do not return to their baseline lung function. Preservation of lung function is important for extending life and for quality of life, thus there is a need to determine the most effective empirical treatments of exacerbations. Antibiotics are a cornerstone of treatment. Most antibiotic regimens are only informed by old, underpowered, or poor-quality trials. Across Australia, CF centres use a range of approaches and antibiotic regimens. No consensus exists on the treatment of pulmonary exacerbations of CF. In addition to numerous antibiotic options, there are other unanswered questions pertaining to the use of mucolytic agents, anti-inflammatory medication and chest physiotherapy, alone and in combination. The range of regimens used for treating CF exacerbations cannot be feasibly compared using conventional clinical trials (comparing one treatment at a time to another treatment or placebo) due to the large number of comparisons that are needed. The aim of BEAT CF is to optimise the management of lung exacerbations in people with CF by systematically evaluating the effectiveness of alternative treatment options, and by implementing these findings in routine care on an ongoing basis. The initial, platform phase of BEAT CF involves the platform database. The platform collects treatment and outcome data in an efficient way from the medical records of participants, for the purpose of evaluating the comparative effectiveness of alternative treatments. The BEAT CF platform is intended to support the data capture for future, nested clinical trials. Details of any future clinical trials will be available separately as and when they are written.

    • Age:

      No Limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US locations

    MAYFLOWERS: Study of pregnancy in women with cystic fibrosis (MAYFLOWERS-OB-20) , protocol number MAYFLOWERS-OB-20 NCT04828382

    This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.

    • Age:

      16 Years and Older

    • Mutation(s):

      No Mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      9

    • Length of Participation:

      35 months

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Indiana, USA

    This is a real-world observational study to assess the impact of Trikafta therapy on the daily use of chronic CF medications and treatments in PwCF using a novel phone-based, patient-reported outcomes application (Folia Health) and data from the CF Foundation Patient Registry. , protocol number HERO-2 (HERO2-OB-2) NCT04798014

    The study will determine the proportion and clinical features of PwCF taking Trikafta who make changes to their chronic daily therapies and assess the relationship between changes in chronic daily therapies in PwCF taking Trikafta using data from the CF Registry. Trikafta and other medications will not be prescribed as part of the study. Participants may be enrolled at participating sites, through social media recruitment, or from existing users of Folia Health. Participation in the study will occur through the Folia application, which is accessed through iPhones, Android phones, and desktop computers. Study participants will be asked to complete an initial survey, log into the app to provide daily data on symptoms and medication use, and complete monthly surveys regarding their symptoms and medication use for 12 months using Folia. Participants are encouraged to track daily, but can “batch track” and provide 7 days of data at once (compensation is based on a minimum of three days of data each week).

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      0

    • Length of Participation:

      12 months

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    STOP-PEDS Pilot: Study to evaluate treatment of pulmonary exacerbations in children 6-18 years old with CF (STOP-PEDS 2.0) , protocol number STOP-PEDS 2.0 NCT04608019

    This study will evaluate children 6 to 18 years old with CF to determine the acceptability and feasibility of a larger trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation treatment.

    • Age:

      6 Years to 18 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      50% or greater

    • Number of Visits:

      3

    • Length of Participation:

      18 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: Australia

    A study evaluating the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients 6 years and older and F/MF genotypes , protocol number VX20-445-119 NCT04545515

    A Phase 3b Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

    • Age:

      Minimum 6 Years

    • Mutation(s):

      F508

    • FEV1% Predicted:

      not specified

    • Number of Visits:

      not specified

    • Length of Participation:

      not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionRecruiting Location: Australia

    A Study to assess the effect of ELX/TEZ/IVA on glucose tolerance in participants with cystic fibrosis , protocol number VX19-445-117 NCT04599465

    A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects With Abnormal Glucose Metabolism

    • Age:

      Minimum age 12 Years

    • Mutation(s):

      F508del

    • FEV1% Predicted:

      30%

    • Number of Visits:

      Not specified

    • Length of Participation:

      No specified

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 218)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|